Head & Neck Cancer

Our program is one of only a handful nation-wide with a robust translational and clinical research program. It has a strong track record of funding over the past 12 years. We have nationally-recognized practices in Robotics, Surgical Oncology/Reconstruction and Radiotherapy for Salivary Gland and Merkel Cell Cancer Programs.

The head and neck multidisciplinary cancer care team ranks as one of the top in the nation. The team includes head and neck surgeons, reconstructive surgeons, dental surgeons, radiation oncologists, medical oncologists, and neuro-radiologists. Our clinicians offer patients the broadest menu of therapy options locally and regionally and the only team in the region offering the newest technique of transoral robotic-assisted surgery. Our clinical and basic science researchers at UW Medicine and Fred Hutchinson Cancer Research Center are identifying new ways to screen, diagnose and treat head and neck cancers. 


This multidisciplinary research program has placed significant emphasis on the field of genomics, which has enormous potential in unlocking the root causes of head and neck cancer and allowing us translate these findings to clinical care. Toward this goal, we have become national leaders in discovering molecular fingerprints that can help physicians determine which cancers are more aggressive than others to help guide oncologists stratify therapies. Over this period of time, we have written numerous publications demonstrating the proof-of-principle that head and neck cancer can be sub classified on the basis of gene aberrations and that these can inform patient survival.

We have now refined this tumor gene signature, the expression of which can predict the most aggressive head and neck cancers with significantly higher accuracy than current clinical parameters alone. We are now translating these findings for clinical use. These clinical applications include the following two highlighted areas:

1) “genomics”: where biomarkers are used to help clinicians predict which tumors are most aggressive on the basis of genetic aberrations

2) “functional genomics”: where genes can be individually “turned off” (or “knocked down” – these terms are interchangeably used) with the use of a naturally occurring molecule termed “siRNA”. Since their discovery, these siRNA’s are now available for each individual gene in the entire human genome. Our NIH-funded functional genomic studies allow us to determine which genetic aberrations drive tumor growth, which could be targeted as new therapies. We are discovering novel targets to treat head and neck cancers, and matching these targets to the tumor subtypes which will respond best to drugs against these targets.

head and neck cancer graphic

Dr. Eduardo Mendez
STTR Head & Neck Cancer Deputy Director

Dr. Mendez specializes in the surgical treatment of head and neck cancer, including reconstruction of head and neck cancer defects. He uses minimally-invasive approaches which include robotic-assisted surgery and transoral laser microsurgery. His research focuses on markers of disease progression in head and neck cancer. He is looking to discover which genes are related to the spread of oral cancer to other parts of the body.

Learn more at the Mendez Lab


ACS Award

ACS awards $720,000 for study of head and neck cancer metastasis to Eduardo Méndez

Seattle MagazineTop Doctors

2013 Seattle Magazine Top Doctors: David Byrd, Renato Martins, Shilpen Patel, Robert Rostomily

Learn More About Head & Neck Cancer

Learn more about diagnosis and treatment of Head & Neck cancer from experts, Drs. Neal Futran and Eddie Mendez. Click the link to watch the video from Seattle Cancer Care Alliance